Dr Reddy's

North America weakness, lower margins, uncertainty over key launches weigh on earnings outlook

The expanding domestic market for semaglutide-based weight-loss drugs is expected to help cushion weaker US sales for Cipla and Dr Reddy's after the loss of Revlimid exclusivity

Dr Reddy's Foundation -- a family-owned trust and one of the key beneficiaries of the CSR funds of pharma major Dr Reddy's Laboratories -- is scaling up operations at its Hyderabad soil testing facility with the lab targeting between 75,000 and 1,00,000 samples ahead of the next Rabi season -- more than double what it processed in its first full year of operations. The move comes amid growing concern over depleting soil health and implementation gaps in the Centre's Soil Health Card scheme rolled out nationally in 2015. "Though the government's soil testing ecosystem exists, the scale of the problem is huge. So we decided to address this issue in our own way," said Suman Saraswathibatla, Director (Rural Livelihoods and Climate Action) at the foundation. This soil testing facility is central to the Foundation's broader soil health and regenerative agriculture programme, under which assessing soil condition is treated as the starting point for any intervention. The push for an in-hou

Drugmaker said certain batches of semaglutide failed to meet quality specifications, prompting a delay in commercial supplies, while maintaining there is no impact on patient safety

Drugmaker said certain batches of semaglutide failed to meet quality specifications, prompting a delay in commercial supplies, while maintaining there is no impact on patient safety

USFDA completed a pre-license inspection of the Hyderabad facility and issued a Form 483 with seven observations, which the company said it will address within the stipulated timeline

The company has launched a generic version of Pfizer's Bosulif for chronic myeloid leukaemia and secured 180 days of exclusivity for the 400 mg strength

The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable efficacy and safety to the innovator drug

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

DRL is the first company to receive market authorisation for a generic semaglutide injection in Canada. It is the first generic semaglutide to be approved in a G7 country

Brazil's regulator Anvisa rejects DRL and Cipla's generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality

Acquisition of Wokadine marks Corona Remedies' entry into India's Rs 648 crore povidone iodine segment, strengthening its specialty portfolio and distribution reach

Court flags phonetic similarity with Novo Nordisk's Ozempic, directs Dr Reddy's to halt expansion amid trademark dispute over diabetes drug branding

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of semaglutide injection used for diabetes and weight management following the molecule behind products like Ozempic and Wegovy going off patent in India. The prices of the generic versions of semaglutide injection are considerably lower than the prices of the innovator, Novo Nordisk. Sun Pharmaceutical Industries launched its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity and is available in five dose strengths -- 0.25 mg/0.5 ml, 0.5 mg/0.5 ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml, and 2.4 mg/0.75 ml, Sun Pharma said in a statement. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise and is available in t

Hyderabad-based Dr Reddy's has applied to trademark the Obeda brand and logo, a government filing showed

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from UK-headquartered Mercury Pharma Group for USD 32.15 million, according to a company statement. Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated. "The acquisition will serve as the spearhead of our expansion into the HRT segment, ...

The company ​last month received an approval from ‌India's drug regulator ​to manufacture ‌and sell the generic version ‌of blockbuster diabetes drug Ozempic

Ozempic is also used off-label for weight loss due to its appetite-suppressing effects

Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth